

## Special Issue

# Autophagic Signatures in Health and Disease: Molecular Insights and Clinical Applications

### Message from the Guest Editors

The aim of this Special Issue is to provide a comprehensive overview of the multifaceted roles of autophagy in health and disease, with a particular focus on the following areas:

- The mechanisms and regulation of selective autophagy (e.g., mitophagy, lipophagy, xenophagy, CMA, ER-phagy);
- Autophagy as a source of diagnostic, prognostic, and predictive disease biomarkers;
- The correlation between autophagic pathways and approved clinical biomarkers;
- The interplay between autophagy and key signaling networks (e.g., inflammation, immunity, metabolism);
- The role of autophagy in tissue homeostasis, cellular stress, and pathogenesis;
- Novel therapeutic strategies targeting autophagy-related pathways;
- Innovative technologies to monitor autophagic flux and specificity in clinical and experimental settings.

We encourage the submission of original research articles, comprehensive reviews, and methodological papers that address these topics and can contribute to expanding our current understanding of autophagy in translational and clinical contexts. You may choose our [Joint Special Issue](#) in *Cells*.

### Guest Editors

Dr. Simone Patergnani

Department of Medical Sciences, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, 44121 Ferrara, Italy

Dr. Alberto Danese

Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy

### Deadline for manuscript submissions

20 February 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/245741](https://mdpi.com/si/245741)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).